JP2024512722A - 免疫原性融合タンパク質 - Google Patents

免疫原性融合タンパク質 Download PDF

Info

Publication number
JP2024512722A
JP2024512722A JP2023560549A JP2023560549A JP2024512722A JP 2024512722 A JP2024512722 A JP 2024512722A JP 2023560549 A JP2023560549 A JP 2023560549A JP 2023560549 A JP2023560549 A JP 2023560549A JP 2024512722 A JP2024512722 A JP 2024512722A
Authority
JP
Japan
Prior art keywords
fusion protein
seq
amino acid
acid sequence
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512722A5 (https=
Inventor
ペダーセン・フィッシャー，ペル・ボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minervax Aps
Original Assignee
Minervax Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minervax Aps filed Critical Minervax Aps
Publication of JP2024512722A publication Critical patent/JP2024512722A/ja
Publication of JP2024512722A5 publication Critical patent/JP2024512722A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560549A 2021-03-29 2022-03-29 免疫原性融合タンパク質 Pending JP2024512722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21165674.9 2021-03-29
EP21165674.9A EP4066854A1 (en) 2021-03-29 2021-03-29 Immunogenic fusion protein
PCT/EP2022/058309 WO2022207657A1 (en) 2021-03-29 2022-03-29 Immunogenic fusion protein

Publications (2)

Publication Number Publication Date
JP2024512722A true JP2024512722A (ja) 2024-03-19
JP2024512722A5 JP2024512722A5 (https=) 2024-12-23

Family

ID=75277909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560549A Pending JP2024512722A (ja) 2021-03-29 2022-03-29 免疫原性融合タンパク質

Country Status (12)

Country Link
US (1) US20240173394A1 (https=)
EP (2) EP4066854A1 (https=)
JP (1) JP2024512722A (https=)
KR (1) KR20230163500A (https=)
CN (1) CN117120081A (https=)
AU (1) AU2022248869A1 (https=)
BR (1) BR112023019757A2 (https=)
CA (1) CA3212987A1 (https=)
IL (1) IL307256A (https=)
MX (1) MX2023011502A (https=)
WO (1) WO2022207657A1 (https=)
ZA (1) ZA202309225B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553166A1 (en) 2023-11-07 2025-05-14 MinervaX ApS Method for preparing a sample for analysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062015A1 (en) * 2007-04-16 2010-03-11 Lunds Universitets Fusion protein vaccine
US20180305415A1 (en) * 2015-10-21 2018-10-25 Minervax Aps Immunogenic fusion protein
US20190282681A1 (en) * 2015-12-30 2019-09-19 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
HU217582B (hu) 1993-03-19 2000-02-28 Gunnar Lindahl Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100062015A1 (en) * 2007-04-16 2010-03-11 Lunds Universitets Fusion protein vaccine
US20180305415A1 (en) * 2015-10-21 2018-10-25 Minervax Aps Immunogenic fusion protein
US20190282681A1 (en) * 2015-12-30 2019-09-19 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL. PHARMACEUTICS, vol. 15, JPN6025046332, 2018, pages 2584 - 2593, ISSN: 0005733267 *

Also Published As

Publication number Publication date
EP4313134A1 (en) 2024-02-07
MX2023011502A (es) 2023-10-19
CA3212987A1 (en) 2022-10-06
AU2022248869A9 (en) 2023-11-09
US20240173394A1 (en) 2024-05-30
AU2022248869A1 (en) 2023-10-26
BR112023019757A2 (pt) 2023-10-31
KR20230163500A (ko) 2023-11-30
EP4066854A1 (en) 2022-10-05
IL307256A (en) 2023-11-01
ZA202309225B (en) 2025-03-26
CN117120081A (zh) 2023-11-24
WO2022207657A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US12173033B2 (en) Immunogenic fusion protein
RU2487890C2 (ru) Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
US11484584B2 (en) Immunogenic complex for eliciting protective immunity against group B Streptococcus
JP2020502075A (ja) 肺炎球菌表面プロテインａの選択されたアルファヘリカルドメインおよびプロリンリッチドメインを組み合わせた肺炎球菌ワクチン
JP2024512722A (ja) 免疫原性融合タンパク質
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
OA21833A (en) Immunogenic fusion protein.
EA051105B1 (ru) Иммуногенный слитый белок
KR20220133632A (ko) Pedv 스파이크 단백질 s1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
HK1250933A1 (en) Immunogenic fusion protein
AU2024337266A1 (en) Products and methods for inducing immune responses to bacteria
EP4511059A1 (en) Streptococcus suis vaccine composition comprising immunogenic fusion polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406